# Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes

> **NCT01342692** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 320 (estimated)

## Conditions studied

- MDS

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Azacitidine associated with Valproic acid
- **DRUG:** Azacitidine associated with Lenalidomide
- **DRUG:** Azacitidine associated with Idarubicine

## Key facts

- **NCT ID:** NCT01342692
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2018-07
- **Final completion:** 2019-06
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342692, "Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01342692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*